Semanteon Capital Management LP Acquires New Shares in Glaukos Co. (NYSE:GKOS)

Semanteon Capital Management LP acquired a new stake in Glaukos Co. (NYSE:GKOS) in the 4th quarter, Holdings Channel reports. The firm acquired 6,686 shares of the medical instruments supplier’s stock, valued at approximately $531,000.

Other hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC purchased a new position in Glaukos in the 4th quarter valued at approximately $55,000. CWM LLC increased its stake in Glaukos by 309.5% in the 3rd quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 1,046 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Glaukos by 17.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $137,000 after purchasing an additional 270 shares in the last quarter. Xponance Inc. purchased a new position in Glaukos during the third quarter worth $208,000. Finally, Mackenzie Financial Corp purchased a new position in Glaukos during the third quarter worth $203,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on GKOS shares. Mizuho raised their price target on Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. StockNews.com downgraded Glaukos from a “hold” rating to a “sell” rating in a research report on Tuesday, February 27th. Wells Fargo & Company raised their price target on Glaukos from $83.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, February 22nd. Truist Financial reissued a “buy” rating and set a $110.00 price target on shares of Glaukos in a research report on Monday, April 8th. Finally, Needham & Company LLC raised their price target on Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $99.80.

Insider Activity at Glaukos

In related news, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $88.25, for a total value of $441,250.00. Following the transaction, the director now owns 30,620 shares in the company, valued at $2,702,215. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $88.25, for a total transaction of $441,250.00. Following the transaction, the director now owns 30,620 shares in the company, valued at $2,702,215. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Mark J. Foley sold 4,560 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $92.87, for a total value of $423,487.20. Following the transaction, the director now owns 33,220 shares in the company, valued at approximately $3,085,141.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 242,357 shares of company stock worth $22,857,372. 6.40% of the stock is owned by insiders.

Glaukos Trading Down 0.6 %

Glaukos stock traded down $0.63 during midday trading on Friday, reaching $99.48. The stock had a trading volume of 288,682 shares, compared to its average volume of 655,646. Glaukos Co. has a twelve month low of $45.38 and a twelve month high of $103.66. The stock has a market capitalization of $4.99 billion, a PE ratio of -35.78 and a beta of 1.08. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34. The stock’s 50-day simple moving average is $92.29 and its 200 day simple moving average is $81.55.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The firm had revenue of $82.40 million during the quarter, compared to analyst estimates of $81.00 million. During the same quarter in the previous year, the business posted ($0.53) EPS. Glaukos’s revenue was up 15.7% compared to the same quarter last year. Analysts expect that Glaukos Co. will post -2.18 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.